RESEARCH ARTICLE

Coronary Atherosclerotic Plaque Detected by Computed Tomographic Angiography in Subjects with Diabetes Compared to Those without Diabetes

Bahram Khazai1*, Yanting Luo2, Steven Rosenberg3, James Wingrove3, Matthew J Budoff2

1 Department of Cardiology, University of Miami Miller School of Medicine, Miami, Florida, United States of America, 2 Department of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA, UCLA School of Medicine, Torrance, California, United States of America, 3 CardioDx, Inc., Palo Alto, California, United States of America

* bahram_khazaee@yahoo.com

Abstract

Objectives

Little data are available regarding coronary plaque composition and semi-quantitative scores in individuals with diabetes; the extent to which diabetes may affect the presence and extent of Coronary Artery Calcium (CAC) needs more evaluation. Considering that this information may be of great value in formulating preventive interventions in this population, we compared these findings in individuals with diabetes to those without.

Methods

Multi-Detector Computed Tomographic (MDCT) images of 861 consecutive patients with diabetes who were referred to Los Angeles Biomedical Research Institute from January 2000 to September 2012, were evaluated using a 15–coronary segment model. All 861 patients underwent calcium scoring and from these; 389 had coronary CT angiography (CTA). CAC score was compared to 861 age, sex and ethnicity matched controls without diabetes after adjustment for Body Mass Index (BMI), family history of coronary artery disease, hyperlipidemia, hypertension and smoking. Segment Involvement Score (SIS; the total number of segments with any plaque), Segment Stenosis Score (SSS; the sum of maximal stenosis score per segment), Total Plaque Score (TPS; the sum of the plaque amount per segment) and plaque composition were compared to 389 age, sex and ethnicity matched controls without diabetes after adjustment for BMI, family history of coronary artery disease, hyperlipidemia, hypertension and smoking.

Results

Diabetes was positively correlated to the presence and extent of CAC (P<0.0001 for both). SIS, SSS and TPS were significantly higher in those with diabetes (P<0.0001). Number of
mixed and calcified plaques were significantly higher in those with diabetes ($P = 0.018$ and $P < 0.001$ respectively) but there was no significant difference in the number of non-calcified plaques between the two groups ($P = 0.398$).

**Conclusions**

Patients with diabetes have higher CAC and semi-quantitative coronary plaque scores compared to the age, gender and ethnicity matched controls without diabetes after adjustment for cardiovascular risk factors. Since mixed plaque is associated with worse long-term clinical outcomes, these findings support more aggressive preventive measures in this population.

**Introduction**

Diabetes Mellitus (DM) is a major risk factor for the early development of coronary artery disease (CAD), and people with type 2 DM (DM2) present with CAD occurring at a much younger age compared to non-DM counterparts [1]. Even patients with DM2 without symptoms of CAD may have significant coronary artery calcium (CAC) [2]. For patients with DM, CAC is an independent correlate of myocardial infarction (MI) [3].

The overall risk for the presence of CAC is four times greater for a young adult with DM than an age-matched person without DM [2, 4]. The risk increases if other comorbidities e.g., hypertension (HTN), dyslipidemia, smoking, and family history of CAD are taken into account. These results suggest that many young adults with DM have clinically silent but potentially serious coronary artery lesions based on radiographic evidence.

In Type 1 Diabetes Mellitus (DM1), CAD is the main cause of death, with 35% mortality caused by CAD in DM1 patients by 55 years of age in contrast to 4% of non-DM women and 8% of non-DM men [5]. The benefits of improved DM care do not appear to have reduced CAD mortality in this population [6]. Traditional risk factors for CAD in DM1 including waist to hip ratio, nephropathy, lipids (both HDL and non-HDL cholesterol), HTN and cigarette smoking are predictors of CAD [7–11], however, not all risk can be accounted for by these factors alone, and therefore, other markers for CAD are under investigation to improve the ability to predict risk and set treatment goals. Haffner et al. showed that the risk of mortality from cardiovascular causes in subjects with DM2 and no previous history of cardiovascular events is equivalent to non-DM subjects with prior myocardial infarction (MI) [12].

This increased risk of significant cardiovascular events from diabetes led to guidelines that all adults over the age of 40 with DM be treated according to the criteria reserved for secondary prevention of CAD [13].

**Use of Coronary Calcium to predict CAD in DM**

The use of computed tomography (CT) for assessment of CAC has been described as an effective risk stratification modality in asymptomatic patients, and specifically recommended by the American College of Cardiology Foundation and American Heart Association (ACCF/AHA) for individuals with DM, due to data showing advanced risk stratification [14, 15]. Markers like CAC have been shown to be a predictor of cardiovascular (CV) events in older patients with DM. CAC is considered a marker of atherosclerosis [2, 16] and an independent
and incremental marker of increased risk of CV events [17]. Furthermore, there is a tight correlation of CAC score to angiographic disease [16–18].

CT coronary angiography to evaluate plaque morphology

A more direct evaluation of atherosclerosis than CAC is the measurement of total plaque in the coronary arteries. This is possible with coronary CT angiography (CCTA). There are concerns that young patients with DM will have lower levels of CAC (and often zero scores), but may have increased non-calcified plaque which can be assessed on cardiac CT angiography.

Recently noninvasive CT-based plaque imaging has been shown to identify the presence and extent of non-calcified atherosclerotic plaque, which is a better measure of early and total atherosclerosis. Further, cardiac CT can detect sub-clinical (asymptomatic) CAD and mild non-obstructive coronary stenosis, which enhances its ability to identify individuals at risk before the inception of disease [19]. Cardiac CT is an accurate, non-invasive and inexpensive test that measures not only CAC, but also non-calcified plaque, stenosis severity, occult scar (old infarction) and thoracic plaque by use of a contrast enhanced scan [20]. Results from cardiac CT have been comparable to those measured at autopsy [19].

Multiple dose reduction strategies, including significant hardware and software advances over the last 3 years, now allow CT angiography to be performed with < 3 mSv doses of radiation, allowing use of this technique to evaluate asymptomatic persons. The scan takes less than 30 minutes [20], and doses administered are lower than annual background radiation doses.

Considering that there is little data available about plaque burden and plaque morphology (mixed, calcified and non-calcified) in patients with DM, we decided to compare these findings in individuals with DM to those without DM.

Materials and Methods

All research involving human participants have been approved by our institutions Institutional Review Board (IRB). Written informed consent was obtained from the participants and saved either as a hard copy or an electronic copy in the patients charts.

We evaluated 861 consecutive patients with DM who were referred to Los Angeles Biomedical Research Institute (Torrance, CA) from January 2000 to September 2012. Major indications were rule out cardiac etiology of chest pain or equivocal exercise stress test results. All 861 underwent calcium scoring and from these; 389 underwent CTA. All patients were older than 18 years and all the subjects provided informed consent. For CTA, we excluded those with known allergy to iodine and serum creatinine of > 1.4 mg/dL. Those with poor quality images, poor contrast enhancement, and with image artifacts (misalignment, motion, and helical interpolation) were excluded from the study.

A 64-slice MDCT scanner (LightSpeed VCT; GE Medical Systems, Milwaukee, WI) was used to obtain CAC and MDCT Image acquisition and post-processing CAC studies.

We used prospective electrocardiographic triggering with a tube voltage of 120 kV and tube currents of 300 to 600 mA on unenhanced scans, and imaged the coronary arteries at a temporal resolution of 227 ms and a slice thickness of 2.5 mm during 75% of the RR interval.

Subjects with a baseline heart rate above 65 beats/ min were given oral Beta-blocker to slow their heart rate. Intravenous metoprolol was given in 5-mg increments to a maximum dose of 40 mg to achieve a resting heart rate < 65 beats/min in subjects who did not achieve heart rate of < 65 with oral Beta-blocker. Finally we scanned all patients eligible for MDCT imaging, irrespective of achieving the goal heart rate of < 65 beats/min.

Sublingual nitroglycerine (0.4 mg) was given prior to contrast injection after obtaining antero-posterior and lateral chest X-ray. 10–20 mL contrast bolus was given to detect optimal
time for contrast opacification at a level immediately superior to the ostium of the left main artery in the axial image (the location was derived from the calcium scan). 60 mL of iodinated contrast (Omnipaque; GE Medical Systems) was subsequently injected using a triple-phase contrast protocol: 40 mL of contrast, followed by 40 mL of a 40:60 mixture of contrast and saline, followed by flush with 50 mL of saline.

We performed retrospective electrocardiographically gated helical contrast-enhanced MDCT imaging. We initiated the scans from 10 mm above the level of the left main artery to 10 mm below the inferior myocardial apex with scan parameters being 64 0.625 mm sections (2.5 mm); with collimation tube currents of 350 to 780 mA and tube voltage of 100 or 120 kV.

Dose modulation techniques were used in all cases to reduce radiation. Multiphase reconstruction of the MDCT scans was performed with reconstructed images from 70% to 80% in 5% increments and 5% to 95% in 10% increments after completion of the scans. The MDCT images were transferred to a reading center for three-dimensional image analysis (Advantage Workstation; GE Healthcare, Milwaukee, WI) at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (Torrance, CA).

An experienced reader blinded to all patient characteristics interpreted all MDCT images. The MDCT image reader was permitted to use any or all available post-processing image reconstruction algorithms, including two-dimensional axial or three-dimensional maximal intensity projection, volume-rendered, multi-planar reformat and cross-sectional analysis techniques.

**Measurement of CAC Score**

We used noncontrast images for CAC scoring. Presence of CAC in a coronary artery was defined as a density of >130 Hounsfield units (HU) in three or more contiguous pixels (>1 mm²) overlying that coronary artery. CAC was quantified by using the Agatston scoring method which has been previously described [21]. We calculated score of each lesion by multiplying the lesion area by the density factor obtained from the maximal HU in that specific area. We considered a density factor of 1 for lesions with a maximum density of 130 to 199 HU, 2 for a maximum density of 200 to 299 HU, 3 for a maximum density of 300 to 399 HU, and 4 for density >400 HU. Sum of the individual lesion scores from each of four anatomic sites (left main, left anterior descending, circumflex, and right coronary arteries) was considered as total calcium score.

**Measurement of Plaque Burden**

We used the 15-segment American Heart Association classification [22] for assessment of coronary arteries. Coronary artery segments with diameters >2 mm measured on MDCT imaging were included in the analysis. Using axial, cross-sectional and curved multi-planar reconstruction images, presence or absence of any atherosclerotic plaque was evaluated in each segment of the coronary arteries. Coronary plaques were defined as structures >1 mm² within and/or adjacent to the coronary artery lumen, which could be clearly distinguished from the surrounding pericardial fat tissue and the contrast-enhanced vessel lumen.

Each coronary segment was assigned one coronary plaque regardless of the number of lesions in that specific segment. We quantified the amount of plaque in each segment as mild (score of 1), moderate (score of 2), or severe (score of 3) using a previously described method [23]. We calculated total plaque score (TPS) by summation of the amount of plaque of each coronary segment (maximum score, 45). The severity of diameter stenosis was assigned a score of 0 for normal (no stenosis), 1 for 1% to 49% stenosis, 2 for 50% to 69% stenosis, and 3 for ≥70% stenosis for each segment. We calculated segment stenosis score (SSS) as the sum of the maximal stenosis score in each segment (maximum score, 45).
In those segments which were found to have multiple stenoses, the segment with highest degree of stenosis was taken for analysis. We determined segment involvement score (SIS) by adding the number of segments with lesions (maximum score, 15). We assessed the morphology of coronary artery plaques visually. Calcified plaques were defined as those with the presence of >50% calcifications. Non-calcified plaques were defined as those with no calcifications in the plaque and partially calcified plaques (mixed plaques) were defined as having <50% calcifications (lesions with density >130 HU).

Covariates

At the baseline visit, age, gender, race (White, Hispanic, Black, Asian and other), BMI (kg/m²), family history of CAD, history of chest pain, hyperlipidemia, HTN and smoking status were recorded. BMI was calculated by dividing weight in kilograms by height in meters squared. Using a Dinamap model Pro 100 automated sphygmomanometer (Critikon, Tampa, FL), right arm resting seated BP was measured two times at 1-minute intervals with average of the two readings used for analysis. HTN was defined as receiving antihypertensive medications or a blood pressure ≥140 mm Hg systolic or 90 mm Hg diastolic [24]. DM was defined as receiving hypoglycemic medications or fasting blood glucose ≥126 mg/dl and dyslipidemia was defined as being on lipid lowering medications or based on criteria reported by ATP III [25].

Statistical Analysis

The data were first analyzed using the Shapiro-Wilk normality test. Continuous variables were presented as mean ± SD or median (quartile 1, quartile 3), and categorical variables were presented as frequency (percentage). For variables with normal distributions, Student t test for two groups was used to determine the statistical significance between the diabetic and non-diabetic groups. For the variables failing the normality test, statistical significance between groups was determined by non-parametric Mann-Whitney U test. To access the categorical variables, the chi-square test was used. For assessing the qualitative relationship between the CACs and semi-quantitative coronary plaque scores with diabetes, the linear regression analysis was performed. Regression coefficients, 95% confidence interval (95% CI) and p-values were reported to characterize both the strength and (statistical) significance. All statistical significance was defined as p < 0.05 (2-tailed). All analyses were performed using SAS software (version 9.4, SAS Institute, Cary, North Carolina).

Results and Discussion

Baseline characteristics of all subjects and those with CTA; are shown in Table 1 and Table 2 respectively. 5.2% of the DM subjects and 4.9% of the controls were 40 years old or younger. The mean age of the total study population (861 patients) was 62.1 ± 12.5 years (63% male). Those with DM had a higher BMI (29.9 ± 7.9 vs 26.0 ± 7.1, P < 0.0001) and a higher prevalence of dyslipidemia (76.2% vs 54.3% P < 0.0001), HTN (77.9% vs 43% P < 0.0001), family history of CAD (66.4% vs 52.6%, P < 0.0001) and history of chest pain (36.1% vs 24.7%, P = 0.014). Prevalence of smoking was not different between the two groups (12.9% vs 10.4%, P = 0.171). Prevalence of CAC > 0 was 84% in those with DM versus 72.5% in non-DM subjects. Mean CAC score was 343 in DM subjects versus 89 in non-DM subjects.

After adjustment for BMI, family history of CAD, history of chest pain, hyperlipidemia, HTN and smoking, among 389 subjects who underwent CTA, SIS (β(Se) = 1.7 (0.3), P < 0.001), SSS (β(Se) = 4.6 (0.8), p < 0.001) and TPS (β(Se) = 3.7 (0.7), P < 0.001) were significantly higher in those with DM (P < 0.0001) compared to those without DM. Number of mixed...
and calcified plaques were significantly higher in those with DM (P = 0.018 and P < 0.001 respectively) but there was no significant difference in the number of non-calcified plaques between the two groups (P = 0.398) (Table 3).

The number of subjects 40 years old or younger undergoing CTA was very small (11 cases, 2.8%) making the analysis on this specific group impossible because of lack of power. Prevalence of calcified and mixed plaques did increase with age unlike the prevalence of non-calcified plaque which decreased with increased age. All plaque scores were significantly increasing with increasing age (Table 4). CAC score was negatively associated with number of non-calcified plaques but was positively correlated with number of calcified plaques and also all plaque scores (SIS, TPS, SSS) (Table 4). Among patients with DM who were referred by their primary care providers to have cardiac CT in our lab for different reasons, we found that the number of mixed and calcified coronary plaques was significantly higher compared to the age, gender and ethnicity matched individuals who did not have DM.

The fact that our DM population had significantly higher report of chest pain in their history even though DM is known to blunt chest pain as a presentation of CAD [26], indicates that they likely had more advanced CAD in comparison to their not-DM counterparts. This was

### Table 1. Baseline risk factor distributions by groups.

|                      | Total (n = 1722,100.0%) | DM (n = 861,50.0%) | Non-DM (n = 861,50.0%) | P       |
|----------------------|------------------------|--------------------|------------------------|---------|
| **Age, year**        | 62.1±12.5              | 62.1±12.5          | 62.1±12.5              | 0.9815  |
| **Age<40 years, n (%)** | 87(5.1)                | 45(5.2)            | 42(4.9)                | 0.7413  |
| **Gender, n (%)**    |                        |                    |                        | 1.000   |
| Male                 | 1084(63.0)             | 542(63.0)          | 542(63.0)              |         |
| Female               | 638(37.0)              | 319(37.0)          | 319(37.0)              |         |
| **Race, n (%)**      |                        |                    |                        | 1.000   |
| White                | 742(43.1)              | 371(43.1)          | 371(43.1)              |         |
| Hispanic             | 432(25.1)              | 216(25.1)          | 216(25.1)              |         |
| Black                | 134(7.8)               | 67(7.8)            | 67(7.8)                |         |
| Asian                | 308(17.9)              | 154(17.9)          | 154(17.9)              |         |
| Others               | 106(6.2)               | 53(6.2)            | 53(6.2)                |         |
| **BMI, kg/m²**       | 27.4±7.6               | 29.9±7.9           | 26.0±7.1               | <.001** |
| **Family History of CAD, n (%)** | 894(58.7) | 451(66.4) | 443(56.2) | <.001** |
| **Chest Pain, n (%)** | 124(28.6)              | 53(36.1)           | 71(24.7)               | 0.014** |
| **Hyperlipidemia, n (%)** | 960(64.4) | 522(76.2) | 438(54.3) | <.001** |
| **Hypertension, n (%)** | 914(59.1) | 556(77.9) | 358(43.0) | <.001** |
| **Current smoker, n (%)** | 151(11.4)  | 66(12.9) | 85(10.4) | 0.171 |
| **Prevalence of CAC (CAC>0), n (%)** | 1347(78.2) | 723(84.0) | 624(72.5) | <.001** |
| **CAC Score**        | 186.5 (3.0–952.0)      | 343.0 (18.0–1215.0)| 89.0 (0.0–683.0)       | <.001** |
| **CAC Score (CAC>0)** | 447.0 (75.0–1220.0)  | 571.0 (116.0–1510.0)| 321.0 (56.5–956.0)     | <.001** |
| **SIScore**          | 3.0 (1.0–7.0)          | 6.0 (3.0–8.5)      | 2.0 (0.0–5.0)          | <.001** |
| **TPScore**          | 4.0 (1.0–10.0)         | 8.0 (3.0–15.0)     | 3.0 (0.0–7.0)          | <.001** |
| **SSScore**          | 4.0 (1.0–10.0)         | 9.0 (3.0–17.0)     | 3.0 (0.0–7.0)          | <.001** |

CAC = coronary artery calcium. Data are expressed as mean ± standard deviation, as number (percentage), or as median (inter-quartile range). There were 389 patients with SIScore, TPScore, or SSScore.

*p<0.05

**p<0.001 across groups

doi:10.1371/journal.pone.0143187.t001
reflected by higher CAC score and also higher prevalence of mixed plaque in our DM patients. Higher CAC score and also higher prevalence of mixed plaques have been both associated with poorer outcome of CVD[27]. These findings signifies the necessity of preventive measures to

Table 2. Baseline risk factor distributions for patients with semi-quantitative scores.

|                      | Total (n = 389) |
|----------------------|----------------|
| **Age, year**        | 62.9±11.1      |
| Age<40 years, n (%)  | 11(2.8)        |
| **Gender, n (%)**    |                |
| Male                 | 189(48.6)      |
| Female               | 200(51.4)      |
| **Race, n (%)**      |                |
| White                | 144(37.0)      |
| Hispanic             | 128(32.9)      |
| Black                | 37(9.5)        |
| Asian                | 67(17.2)       |
| Others               | 13(3.3)        |
| **BMI, kg/m²**       | 27.5±8.0       |
| **Family History, n (%)** | 181(47.8)     |
| **Chest Pain, n (%)** | 120(31.3)      |
| **Hyperlipidemia, n (%)** | 196(53.0)     |
| **Hypertension, n (%)** | 200(52.5)     |
| **Current smoker, n (%)** | 37(10.1)      |
| **Prevalence of CAC (CAC>0), n (%)** | 276(71.0)    |
| **CAC Score**        | 64.0 (0.0–495.0) |
| **CAC Score (CAC>0)** | 215.5 (40.0–652.0) |
| **SIScore**          | 3.0 (1.0–7.0)  |
| **TPScore**          | 4.0 (1.0–10.0) |
| **SSScore**          | 4.0 (1.0–10.0) |

CAC = coronary artery calcium. Data are expressed as mean ± standard deviation, as number (percentage), or as median (inter-quartile range).

doi:10.1371/journal.pone.0143187.t002

Table 3. Multiple regression analysis between number of plaques and DM (N = 389).

|                          | Unadjusted Model | Adjusted Model |
|--------------------------|------------------|----------------|
|                          | β(Se)            | 95% C.I.       | P       | β(Se)            | 95% C.I.       | P       |
| **Number of Non-Calcified Plaques** | 0.0 (0.1) | -0.3,0.2 | 0.794 | -0.1 (0.1) | -0.4,0.2 | 0.398 |
| **Number of Mixed Plaque**     | 0.6 (0.1) | 0.3,0.8 | <0.001** | 0.3 (0.1) | 0.1,0.6 | 0.018* |
| **Number of Calcified Plaque** | 1.1 (0.2) | 0.7,1.4 | <0.001** | 0.8 (0.2) | 0.4,1.2 | <0.001** |
| **SIScore**                | 2.5 (0.3) | 1.8,3.2 | <0.001** | 1.7 (0.3) | 1.1,2.4 | <0.001** |
| **TPScore**                | 5.0 (0.7) | 3.7,6.3 | <0.001** | 3.7 (0.7) | 2.4,5.0 | <0.001** |
| **SSScore**                | 6.1 (0.7) | 4.6,7.5 | <0.001** | 4.6 (0.8) | 3.1,6.2 | <0.001** |

Adjusted by BMI, family history of CAD, history of chest pain, hyperlipidemia, HTN, smoking status.
*p<0.05
**p<0.001

doi:10.1371/journal.pone.0143187.t003
Prevention requires effective diagnostic techniques to identify people at risk before the onset of severe clinical events. Assessment of reversal and prevention requires application of noninvasive procedures that accurately quantify the extent of coronary atherosclerosis. CAC measured by cardiac CT is noninvasive, and have been shown to correlate with asymptomatic and symptomatic CAD. A large number of longitudinal studies have now demonstrated a strong predictive relationship between the extent of CAC and the frequency of subsequent clinical events [28, 29]. This predictive relationship is present among both men and women and across all ethnicities. The ACCF/AHA guidelines for assessment of cardiovascular risk in asymptomatic adults contain for the first time a Class IIa indication for CAC scanning in asymptomatic patients with DM [30]. In previous studies, the measured CAC in persons with DM without known CAD was similar to that found in adults without DM with known CAD [2, 4, 31].

On the other hand as calcification may be a late finding in the pathogenesis of atherosclerosis, it may underestimate CAD, especially in a younger DM population and it has been demonstrated that there is not a linear relationship between CAC and overall plaque burden; consequently CAC may not be a sufficient tool to determine overall plaque burden [32, 33].

The assessment of mixed plaques by CT-angiography may allow for improved cardiovascular risk stratification and determine the presence of early atherosclerosis in patients with DM.

Unfortunately the number of patients with DM who were younger than 40 in our study was not enough to provide us with statistical power for further comparison of CAC score and semi-quantitative plaque scores to those without DM.

CAC data on young persons with DM is very limited. Starkman et al measured CAC in young adults with DM of for at least 5 years and found that 10.9% had CAC [34]. Hoff et al found that younger individuals with DM had CAC comparable to older adults without DM, but the population with patients aged <40 were few [35].

Conclusions

Our findings of higher CAC score and higher prevalence of mixed plaque in patients with DM versus those without DM reinforces the benefits of CAC scoring and CTA in detection of CAD in DM subjects. However the fact that our study subjects were referred for further evaluation for CAD which will introduce bias by itself; and also the small number of cases younger than 40 and lack of control group warrants further studies on asymptomatic DM patients of different types with focus on younger ages and with inclusion of a healthy control group. This can provide meaningful data for formulating preventive strategies in individual with DM and to

|                         | CAC  | Age  |
|-------------------------|------|------|
| SIScore                 | 0.50** | 0.34** |
| TPScore                 | 0.66** | 0.33** |
| SSScore                 | 0.60** | 0.30** |
| Number of Non-Calciified Plaques | -0.20** | -0.04   |
| Number of Mixed Plaque  | 0.18** | 0.13*  |
| Number of Calciified Plaque | 0.55** | 0.35**  |

*p<0.05
**p<0.001
doi:10.1371/journal.pone.0143187.t004
decrease their CVD morbidity and mortality. This could inform future screening and treatment of CAD in DM, and thus will be of high clinical impact and will be the key for developing new strategies to reduce CAD-related morbidity and mortality among persons with DM including younger patients.

The strength of our study is the large number of cases with DM with available semi-quantitative scores reported from one center. We have previously showed a high degree of interobserver agreement in the measurement of plaque amount [23] and reproducibility of our reports[36].

There are also some limitations to our study. First, we did not know subtypes of DM in our population and the epidemiology of CAD and also associated CVD risk factors might be different in DM1 versus DM2. Second, we did not have a control group to compare our findings to a healthy asymptomatic population.

Acknowledgments

We thank other investigators, the staff, and the participants in this study for their valuable contributions. This material is the result of work supported by the Endocrinology, Metabolism and Nutrition training Grant (T32 DK007571) to Los Angeles Biomedical Research Institute.

Author Contributions

Conceived and designed the experiments: BK YL MB. Performed the experiments: BK YL SR JW MB. Analyzed the data: BK YL SR JW MB. Contributed reagents/materials/analysis tools: BK YL MB. Wrote the paper: BK YL SR JW MB. Critically revised for important intellectual content: BK YL SR JW MB. Approved final manuscript: BK YL SR JW MB.

References

1. Palumbo PJ, Elveback LR, Chu CP, Connolly DC, Kurland LT. Diabetes mellitus: incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945–1970. Diabetes. 1976; 25 (7):566–73. PMID:1084308.
2. Khaleeli E, Peters SR, Bobrowsky K, Oudiz RJ, Ko JY, Budoff MJ. Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: Implications for management. American heart journal. 2001; 141(4):637–44. doi:10.1067/mhj.2001.113224 PMID: 11275932.
3. Olson JC, Edmundowicz D, Becker DJ, Kuller LH, Orchard TJ. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes. 2000; 49(9):1571–8. PMID:10969842.
4. Mielke CH, Shields JP, Broemelind LD. Coronary artery calcium, coronary artery disease, and diabetes. Diabetes research and clinical practice. 2001; 53(1):55–61. PMID:11378214.
5. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. The American journal of cardiology. 1987; 59(8):750–5. PMID: 3825934.
6. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes care. 2006; 29(11):2528–38. doi: 10.2337/dc06-1161 PMID: 17065698.
7. Williams KV, Erbay JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000; 49(4):626–32. PMID: 10871201.
8. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arteriosclerosis, thrombosis, and vascular biology. 1996; 16 (6):720–6. PMID: 8640398.
9. Orchard TJ, Olson JC, Erbay JR, Williams K, Forrest KY, Smithline Kinder L, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes care. 2003; 26 (5):1374–9. PMID: 12716791.
10. Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis. 2000; 146(1):159–69. PMID: 10580182.
11. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Rebold P, Michel G, et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes care. 2004; 27(2):530–7. PMID: 14747240.

12. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England journal of medicine. 1998; 339(4):229–34. doi: 10.1056/NEJM199807233390404 PMID: 9673301.

13. Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes care. 1998; 21(1):179–82. PMID: 9538989.

14. Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. European heart journal. 2008; 29(18):2244–51. doi: 10.1093/eurheartj/ehn279 PMID: 1853867.

15. Budoff MJ. Point: Diabetic Patients and Coronary Calcium: Risk stratification, compliance, and plaque progression. Diabetes care. 2003; 26(2):541–2. PMID: 12547998.

16. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001; 104(15):1863–7. PMID: 11591627.

17. Budoff MJ, Yu D, Nasir K, Mehrotra R, Chen L, Takasu J, et al. Diabetes and progression of coronary calcium under the influence of statin therapy. American heart journal. 2005; 149(4):695–700. doi: 10.1016/j.ahj.2004.07.034 PMID: 15990755.

18. Rumberger JA, Sheedy PF 3rd, Breen JF, Schwartz RS. Coronary calcium, as determined by electron beam computed tomography, and coronary disease on arteriogram. Effect of patient’s sex on diagnosis. Circulation. 1995; 91(5):1363–7. PMID: 7867174.

19. Callister TQ, Raggi P, Cool B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. The New England journal of medicine. 1998; 339(27):1972–8. doi: 10.1056/NEJM199812313392703 PMID: 9869668.

20. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. Journal of the American College of Cardiology. 1998; 31(1):126–33. PMID: 9426030.

21. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. Journal of the American College of Cardiology. 1990; 15(4):827–32. PMID: 2407762.

22. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975; 51(4 Suppl):5–40. PMID: 1116248.

23. Pagali SR, Madaj P, Gupta M, Nair S, Hamirani YS, Min JK, et al. Interobserver variations of plaque severity score and segment stenosis score in coronary arteries using 64 slice multidetector computed tomography: a substudy of the ACCURACY trial. Journal of cardiovascular computed tomography. 2010; 4(5):312–8. doi: 10.1016/j.jcct.2010.05.018 PMID: 20630819.

24. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Archives of internal medicine. 1997; 157(21):2413–46. PMID: 9385294.

25. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143–421. PMID: 1248996.

26. Margolis JR, Kannel WS, Feinleib M, Dawber TR, McNamara PM. Clinical features of unrecognized myocardial infarction—silent and symptomatic. Eighteen year follow-up: the Framingham study: The American journal of cardiology. 1973; 32(1):1–7. PMID: 4713110.

27. Russo V, Zavalloni A, Bacchi Reggiani ML, Buttazzi K, Gostoli V, Bartolini S, et al. Incremental prognostic value of coronary CT angiography in patients with suspected coronary artery disease. Circulation Cardiovascular imaging. 2010; 3(4):351–9. doi: 10.1161/CIRCIMAGING.109.880625 PMID: 20460497.

28. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation. 1996; 94(5):1175–92. PMID: 8790070.
29. Budoff MJ, Georgiou D, Brody A, Agatston AS, Kennedy J, Wolfkiel C, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study. Circulation. 1996; 93(5):898–904. PMID:8598080.

30. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010; 122(25):2748–64. doi:10.1161/CIR.0b013e3182051bab PMID:21098427.

31. Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. Journal of the American College of Cardiology. 2004; 43(9):1663–9. doi:10.1016/j.jacc.2003.09.068 PMID:15120828.

32. Weiss RM. Another calcium paradox? Arteriosclerosis, thrombosis, and vascular biology. 2001; 21(10):1561–2. PMID:11597924.

33. Choi TY, Li D, Nasir K, Zeb I, Sourayanezhad S, Gupta M, et al. Differences in coronary atherosclerotic plaque burden and composition according to increasing age on computed tomography angiography. Academic radiology. 2013; 20(2):202–8. doi:10.1016/j.acra.2012.09.017 PMID:23099239.

34. Starkman HS, Cable G, Hala V, Hecht H, Donnelly CM. Delineation of prevalence and risk factors for early coronary artery disease by electron beam computed tomography in young adults with type 1 diabetes. Diabetes care. 2003; 26(2):433–6. PMID:12547875.

35. Hoff JA, Quinn L, Sevrukov A, Lipton RB, Daviglus M, Garside DB, et al. The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease. Journal of the American College of Cardiology. 2003; 41(6):1008–12. PMID:12651050.

36. Cheng VY, Nakazato R, Dey D, Gurudevan S, Tabak J, Budoff MJ, et al. Reproducibility of coronary artery plaque volume and composition quantification by 64-detector row coronary computed tomographic angiography: an intraobserver, interobserver, and interscan variability study. Journal of cardiovascular computed tomography. 2009; 3(5):312–20. doi:10.1016/j.jcct.2009.07.001 PMID:19709947.